Market Cap: $2.27B
AI
Aurinia Pharmaceuticals Inc.
AUPH
NASDAQ (NASDAQ Global Market)USD
Market Cap: $2.27B
Aurinia Pharmaceuticals (Ticker: AUPH) has made a significant announcement during the EULAR 2026 Congress regarding its drug LUPKYNIS. A recently conducted Phase 3 analysis known as AURORA 1 has revea…
Aurinia Pharmaceuticals (Ticker: AUPH) recently unveils promising results from the AURORA 1 Phase 3 clinical trial at the EULAR 2026 international rheumatology congress. The new findings demonstrate t…
Aurinia Pharmaceuticals (Ticker: AUPH) announces significant strides in its clinical research during the recent EULAR 2026 international rheumatology congress. The company reveals compelling findings…
Aurinia Pharmaceuticals Embraces Leadership Change to Propel Future Growth Aurinia Pharmaceuticals is undergoing a significant leadership transition as Kevin Tang steps into the role of chief executiv…
Aurinia Pharmaceuticals Announces Leadership Transition as It Aims for Growth in Autoimmune Treatments Aurinia Pharmaceuticals embarks on a new chapter with the announcement of a leadership transition…
Aurinia Pharmaceuticals Charts Future Growth Trajectory Amid Strong Q4 Performance Aurinia Pharmaceuticals, recognized for its innovative treatments in the autoimmune disease sector, experience a nota…
Aurinia Pharmaceuticals: Pioneering Therapeutics for Kidney Diseases Aurinia Pharmaceuticals stands at the forefront of innovation in treating kidney diseases, particularly through its flagship drug,…
Aurinia Pharmaceuticals: A Promising Path Forward in Lupus Nephritis Treatment Aurinia Pharmaceuticals is making significant strides in the biopharmaceutical sector, particularly in the treatment of k…
### Aurinia Pharmaceuticals: Pioneering Advances in Lupus Nephritis Treatment Aurinia Pharmaceuticals is making significant strides in the biopharmaceutical landscape, particularly with its flagship d…
Aurinia Pharmaceuticals: Navigating a Competitive Landscape in Nephrology Aurinia Pharmaceuticals stands at a pivotal moment as it focuses on enhancing its position within the rapidly evolving nephrol…
FDA Leadership Shakeup: Implications for Drug Regulation and Industry Trust The recent resignation of George Tidmarsh, head of the FDA's drug center, sends shockwaves through the pharmaceutical indust…
FDA Leadership Crisis Raises Ethical Concerns in Pharmaceutical Regulation The recent resignation of George Tidmarsh, the head of the FDA’s drug center, brings to light critical ethical issues within…
Aurinia Pharmaceuticals Faces Regulatory Scrutiny Following FDA Leadership Shakeup The recent resignation of George Tidmarsh, the head of the Food and Drug Administration (FDA) drug center, raises sig…
Aurinia Pharmaceuticals Advances in Autoimmune Disease Treatment Aurinia Pharmaceuticals is at the forefront of innovation in the treatment of autoimmune diseases, particularly with its flagship produ…
Aurinia Pharmaceuticals: A Strong Earnings Turnaround Signals Growth Potential Aurinia Pharmaceuticals Inc. reports a remarkable turnaround in its first-quarter earnings, achieving a profit of 16 cent…
Aurinia Pharmaceuticals: A Transformative Quarter Signals Future Growth Aurinia Pharmaceuticals Inc. achieves a remarkable turnaround in its first-quarter earnings, reporting a profit of 16 cents per…
Aurinia Pharmaceuticals Endorses New Lupus Nephritis Guidelines, Highlighting LUPKYNIS's Role Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) expresses strong support for the American College of Rheumatol…
Enhanced Screening for Lupus Nephritis: A Call to Action at ACR 2024 Aurinia Pharmaceuticals Inc. announces the acceptance of four poster presentations for the upcoming American College of Rheumatolog…
Aurinia Pharmaceuticals Prepares for Jefferies Healthcare Conference Aurinia Pharmaceuticals Inc., a biopharmaceutical company with a specialized focus on therapies for autoimmune diseases, gears up f…
Aurinia Pharmaceuticals Strengthens Position in Autoimmune Disease Treatment Aurinia Pharmaceuticals Inc. showcases its robust financial performance for the third quarter of 2024, reflecting a strateg…